Please use this identifier to cite or link to this item:
|dc.title||A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer|
|dc.identifier.citation||Bible, K.C., Suman, V.J., Menefee, M.E., Smallridge, R.C., Molina, J.R., Maples, W.J., Karlin, N.J., Traynor, A.M., Kumar, P., Goh, B.C., Lim, W.-T., Bossou, A.R., Isham, C.R., Webster, K.P., Kukla, A.K., Bieber, C., Burton, J.K., Harris, P., Erlichman, C. (2012-09). A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 97 (9) : 3179-3184. ScholarBank@NUS Repository. https://doi.org/10.1210/jc.2012-1520|
|dc.description.abstract||Context/Objectives: Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC). Design/Setting/Patients/Interventions/ Outcome Measures: Preclinical studies, followed by a multicenter single arm phase 2 trial of continuously administered 800 mg pazopanib daily by mouth (designed to provide 90% chance of detecting a response rate of >20% at the 0.10 significance level when the true response rate is >5%), were undertaken. The primary trial end point was Response Evaluation Criteria in Solid Tumors (RECIST) response. Results: Pazopanib displayed activity in the KTC2 ATC xenograft model, prompting clinical evaluation. Sixteen trial patients were enrolled; 15 were treated: 66.7% were female, median age was 66 yr (range 45-77 yr), and 11 of 15 had progressed through prior systemic therapy. Enrollment was halted, triggered by a stopping rule requiring more than one confirmed RECIST response among the first 14 of 33 potential patients. Four patients required one to two dose reductions; severe toxicities (National Cancer Institute Common Toxicity Criteria-Adverse Events version 3.0 grades >3) were hypertension (13%) and pharyngolaryngeal pain (13%). Treatment was discontinued because of the following: disease progression (12 patients), death due to a possibly treatmentrelated tumor hemorrhage (one patient), and intolerability (radiation recall tracheitis and uncontrolled hypertension, one patient each). Although transient disease regression was observed in several patients, there were no confirmed RECIST responses. Median time to progression was 62 d; median survival time was 111 d. Two patients are alive with disease 9.9 and 35 months after the registration; 13 died of disease. Conclusions: Despite preclinical in vivo activity in ATC, pazopanib has minimal single-agent clinical activity in advanced ATC. Copyright © 2012 by The Endocrine Society.|
|dc.contributor.department||DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE|
|dc.description.sourcetitle||Journal of Clinical Endocrinology and Metabolism|
|Appears in Collections:||Staff Publications|
Show simple item record
Files in This Item:
There are no files associated with this item.
checked on Jun 7, 2021
WEB OF SCIENCETM
checked on Jun 7, 2021
checked on Jun 6, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.